Jane Doe

It's unusual because it's controlled by a nonprofit foundation in Denmark. And by Denmark's standards, there are actually quite a few of these among their larger companies. And it's essentially a way for Denmark, which, you know, is a country that has some socialist aspects, to embrace capitalism, but in a way that they feel helps benefit more than just the shareholders of a company.

It's unusual because it's controlled by a nonprofit foundation in Denmark. And by Denmark's standards, there are actually quite a few of these among their larger companies. And it's essentially a way for Denmark, which, you know, is a country that has some socialist aspects, to embrace capitalism, but in a way that they feel helps benefit more than just the shareholders of a company.

It's unusual because it's controlled by a nonprofit foundation in Denmark. And by Denmark's standards, there are actually quite a few of these among their larger companies. And it's essentially a way for Denmark, which, you know, is a country that has some socialist aspects, to embrace capitalism, but in a way that they feel helps benefit more than just the shareholders of a company.

To do things like invest in medical research or life sciences in some way that they feel potentially can help people in the future.

To do things like invest in medical research or life sciences in some way that they feel potentially can help people in the future.

To do things like invest in medical research or life sciences in some way that they feel potentially can help people in the future.

He spent pretty much his entire career at the company. He started out as a health economist, very much a creature of the Novo culture.

He spent pretty much his entire career at the company. He started out as a health economist, very much a creature of the Novo culture.

He spent pretty much his entire career at the company. He started out as a health economist, very much a creature of the Novo culture.

His tenure, I would say, would have been the envy of many CEOs in any industry. During that time, the company's stock price, at least until the middle of last year, went up something like 600%.

His tenure, I would say, would have been the envy of many CEOs in any industry. During that time, the company's stock price, at least until the middle of last year, went up something like 600%.

His tenure, I would say, would have been the envy of many CEOs in any industry. During that time, the company's stock price, at least until the middle of last year, went up something like 600%.

And sales were through the roof.

And sales were through the roof.

And sales were through the roof.

He oversaw this big change at the company where they went from this very reliable supplier of insulin to now having these newer types of drugs to help first treat diabetes and then weight loss.

He oversaw this big change at the company where they went from this very reliable supplier of insulin to now having these newer types of drugs to help first treat diabetes and then weight loss.

He oversaw this big change at the company where they went from this very reliable supplier of insulin to now having these newer types of drugs to help first treat diabetes and then weight loss.

And so it was during his tenure that the company came out with Wegovy around 2021, the same drug, but specifically for weight loss.

And so it was during his tenure that the company came out with Wegovy around 2021, the same drug, but specifically for weight loss.